August 2026

novo is running three phase 3 programs right now — two launched this year

Novo Nordisk's amycretin — internally coded NN9487, a dual GLP-1 and amylin receptor agonist — entered Phase 3 in February 2026, when the AMAZE obesity trial opened enrollment targeting 1,150 participants. The AMBITION program, a separate Phase 3 in type 2 diabetes, is scheduled to launch in the second half of 2026, meaning its launch window is open right now in August 2026. What drove Novo into three concurrent trial arms was a set of early data points that caught the obesity-pharmacology world off guard: in Phase 1, an oral version of amycretin showed 13% body-weight reduction at 12 weeks against a 1% placebo response — roughly double what Wegovy produces at the same checkpoint. [FierceBiotech covered the Phase 3 program announcement](https://www.fiercebiotech.com/biotech/novo-nordisk-plots-phase-3-trials-next-gen-obesity-asset-amycretin) in detail. That number needs serious context before anyone builds a forecast from it, but Novo built a Phase 3 program instead, which is an entirely different kind of commitment.

The actual biology

amycretin puts two separate satiety signals into one molecule — that's the mechanism being tested

GLP-1 receptor agonists — semaglutide, tirzepatide, and most of what dominates the weight-loss conversation right now — work primarily through the gut-brain axis. They slow gastric emptying, suppress appetite signaling through vagal and central pathways, and reduce postprandial glucagon. That mechanism works, and the limitations — weight-loss plateaus, rapid regain after discontinuation, GI side effects at high doses — come from what GLP-1 alone cannot do. Amylin is a different signal. It is a peptide hormone released from pancreatic beta cells alongside insulin after meals, and its biological role is complementary to GLP-1 without being identical to it: amylin acts on receptors in the hypothalamus and brainstem to reduce food intake, inhibit glucagon secretion, and slow gastric emptying through pathways that do not fully overlap with the GLP-1 mechanism. The approved amylin analog pramlintide works but requires multiple daily injections. The investigational cagrilintide — Novo's long-acting amylin analog, tested as CagriSema paired with semaglutide — delivered meaningful weight loss but the combination's pivotal obesity trial came up short of the 25% expectation that Wall Street had priced in. Amycretin takes a different approach: one compound targeting both GLP-1 and amylin receptors simultaneously, on the theory that unified signaling produces more predictable satiety than two separate molecules administered together. The [PubMed literature on amycretin](https://pubmed.ncbi.nlm.nih.gov/?term=Amycretin) gives the mechanistic background for the dual-receptor hypothesis.

The wellness pitch

a march 2024 number from 16 people got treated online as if phase 3 data already existed

The March 2024 Phase 1 readout from just 16 of 144 planned participants became, in parts of the biohacking and metabolic-wellness media, the foundational document for amycretin's reputation. The number — 13% body-weight reduction at 12 weeks against 1% for placebo — was real and notable, but the context is essential: 16 people, ascending-dose Phase 1 protocol, no long-term follow-up. The comparison to Wegovy at the same timeframe was accurate in the narrow sense: semaglutide doses slowly, and Wegovy's 12-week numbers lag its 68-week results substantially. 'Doubles Wegovy' is directionally right for that specific comparison, but it says nothing about what amycretin will do in a heterogeneous Phase 3 population of more than 1,000 people over three years. The November 2025 Phase 2 data gave a more grounded picture: in type 2 diabetes patients on metformin, subcutaneous amycretin showed up to 14.5% weight loss and oral amycretin reached 10.1%, both versus placebo. Both are meaningful Phase 2 numbers. Neither is the Phase 3 obesity result, which will not exist until the AMAZE primary completion date in 2029.

What the data says

phase 2 worked in t2d — the phase 3 obesity completion date is 2029

The Phase 2 type 2 diabetes trial enrolled 448 participants on stable metformin with or without SGLT2 inhibitors. Subcutaneous amycretin showed up to 14.5% weight reduction and up to 1.8% HbA1c reduction versus placebo, with 89% of participants at the highest dose reaching HbA1c below 7%. The oral formulation delivered up to 10.1% weight loss and 1.5% HbA1c reduction. [Novo Nordisk's Phase 2 readout published via BioSpace](https://www.biospace.com/press-releases/novo-nordisk-phase-2-trial-with-amycretin-reports-significant-weight-loss-and-hba1c-reduction-in-type-2-diabetes) covers the complete data set. The [ClinicalTrials.gov record for amycretin](https://clinicaltrials.gov/search?term=Amycretin) confirms the AMAZE Phase 3 obesity trial opened in February 2026, targeting 1,150 participants, with a primary completion date of June 2029. Tolerability in Phase 2 was described as consistent with incretin and amylin-based therapies — meaning nausea and GI effects are present and expected at effective doses, the same profile clinicians already manage with GLP-1 drugs. The science justifies Phase 3. Phase 3 being underway does not justify claiming the drug works at scale before those results arrive.

Early human — PeptideFactCheck stance

the mechanism is real, the phase 2 is promising, and the phase 3 is three years from completion

Amycretin carries the Early human evidence tier: real human data from Phase 2, a biologically coherent mechanism, and active Phase 3 trials. That is more than most peptides discussed online in August 2026 can claim. It is also a very different category from an approved therapy with official labeling. The dual-receptor hypothesis — one molecule targeting GLP-1 and amylin simultaneously — is genuinely novel in the obesity-pharmacology space and directly addresses the limitation that cagrilintide plus semaglutide exposed: combining two drugs does not guarantee their signals compose cleanly. Whether a unified molecule solves that problem at scale is what the AMAZE trial is designed to find out. The [PubMed literature on amycretin](https://pubmed.ncbi.nlm.nih.gov/?term=Amycretin) is building but remains early relative to what Phase 3 results will eventually provide. The [FDA's ongoing enforcement posture toward unapproved GLP-1 products](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) applies fully to any amycretin sold outside Novo's clinical trials — meaning research-grade or gray-market amycretin products circulating in August 2026 are not the compound AMAZE is testing, and none of Novo's Phase 2 quality controls apply to them. This is one of the more legitimate stories in obesity pharmacology right now. The mechanism is real, the company's commitment is serious, and the Phase 3 is underway. The receipts will be ready in 2029.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.